Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 Diabetes
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of alogliptin and metformin
fixed-dose combination (FDC) as compared with alogliptin alone or metformin alone on Type 2
Diabetes Mellitus (T2DM).